Barclays Maintains Equal-Weight on Humacyte, Raises Price Target to $0.6
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Barclays analyst Christopher Pasquale maintains Humacyte (NASDAQ:HUMA) with a Equal-Weight and raises the price target from $0.5 to $0.6.
Barclays analyst Christopher Pasquale maintains Humacyte (NASDAQ:HUMA) with a Equal-Weight and raises the price target from $0.5 to $0.6.
